https://www.selleckchem.com/CDK.html
ollow up was 60.0 months. Immunological response improved in the Tα1 group compared with the control group (P less then .001) but the virologic response was similar between 2 groups after 24 months. Patients with Tα1 therapy had better RFS and OS before (P = .018 and P less then .001) and after (P = .006 and P less then .001) propensity matching. Multivariate analysis revealed that Tα1 therapy was an independent prognostic factor for both OS (P less then .001, HR = 0.308, 95% CI 0.175-0.541) and RFS (P less then .001, HR = 0.381, 95% CI 0.
Like
Comment
Share
